Antimicrobial resistance (AMR) poses a serious global public health threat. Without concerted and comprehensive action, it could lead to millions of deaths, with much progress in life expectancy over the last half century undone.
The inaugural Antimicrobial Resistance conference in London in 2019 established the need for greater attention to this public health threat. Now, The Economist is taking the event to Asia. With a population of over four billion people, the continent will prove a lynchpin in the global fight against AMR. Asian food and drug companies, governments, health agencies and universities must play a role in developing new diagnostics and antibiotic solutions, ensure stewardship and rational use, and work to improve public awareness.
This event will explore how AMR could undermine the Sustainable Development Goals (SDGs) in Asia, whose past economic success has done so much to drive global development progress. It will bring together health, food and agriculture voices to explore AMR under the ‘One Health’ rubric in which it is best understood - especially in the Asian context.
While establishing the AMR risk in Asia, the event, mirroring the London 2020 agenda, will be forward-looking and look at positive success stories and innovations, including public education campaigns, improvements in diagnostic technologies, data collaboration, and academic partnerships between regional and international universities. Country deep-dive sessions in Vietnam, China and Japan will show how countries at different income levels are mounting their AMR response.
The Antimicrobial Resistance Summit Asia, by convening experts from government, industry and academia, and from contexts ranging from Cambodia, Indonesia and Vietnam through the South Korea and Singapore, will take AMR from an issue receiving attention by a narrow group of concerned scientists and politicians, to a mainstream policy priority for governments across the world.